Navigation Links
SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393
Date:6/30/2008

SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals (Nasdaq: SGXP) today announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for SGX393. This compound is an internally developed, selective, orally-bioavailable small molecule for the treatment of relapsed and refractory chronic myelogenous leukemia (CML).

The standard of care for CML is Gleevec(R). Although Gleevec is a highly effective front-line therapy for CML, there are patients who relapse while on Gleevec or who are intolerant to the therapy. In the majority of cases, relapses have been linked to the emergence of a number of drug-resistant mutant forms of the tyrosine kinase BCR-ABL. The single mutant that has been the most challenging to inhibit is the T315I mutant. Neither Gleevec nor the two more recently approved CML treatments, Sprycel(R) and Tasigna(R), inhibit the T315I mutant. SGX393 inhibits both wild-type BCR-ABL and many drug resistant mutant forms of BCR-ABL, including the T315I mutation.

"Filing of this IND submission represents another testament to our internal capabilities. We continue to focus on moving our discovery and development programs forward," said Mike Grey, CEO of SGX Pharmaceuticals.

About SGX393

SGX393 was discovered by SGX utilizing FAST(TM), its fragment based approach to drug discovery. SGX393 initially fell within the purview of the Company's collaboration with the Novartis Institute for Biomedical Research (Novartis). SGX obtained the right to further develop and commercialize SGX393 following an amendment to its agreement with Novartis that was signed in September 2007, and it is subject to a reacquisition right of Novartis which may be exercis
'/>"/>

SOURCE SGX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. VIA Pharmaceuticals Set to Join Russell Microcap Index
2. Wyeth Pharmaceuticals Announces Organizational Change
3. Access Pharmaceuticals Presents New Data at International Symposium Showing Companys Angiolix(R) Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells
4. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
5. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
6. Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development
7. Brian Levy, OD, MSc, Named Chief Operating Officer of Danube Pharmaceuticals
8. Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
9. Onyx Pharmaceuticals to Present at Jefferies 2nd Annual Healthcare Conference
10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Immtech Pharmaceuticals and Beijing Capital Medical University Announce Joint Venture to Provide Contract Research Services in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... According to Jeff Howell, Partner of Nidea ... new development in Downtown Toronto is expanding at a ... 755 storeys of new development last week (including three ... dominating the Toronto skyline for the foreseeable future in ... for new development. , As the Toronto city council ...
(Date:9/15/2014)... 16, 2014 Cancer Immunotherapy ... Adoptive T-cell Therapies is a new market research ... the three principal types of therapeutics that have ... in cancer immunotherapy (which is often called "immuno-oncology") ... and Adoptive cellular immunotherapy. , The regular ...
(Date:9/15/2014)... fast when a patient has sepsis, a life-threatening condition ... blood -- often too fast for antibiotics to help. ... developed by a team at Harvard,s Wyss Institute for ... treat sepsis. , "Even with the best current ... at least 30 percent of the time," said Mike ...
(Date:9/15/2014)... , Sept. 15, 2014 Zymo ... viral transport solution for safe ambient temperature storage ... molecular testing. Importantly, the infectivity of agents in such ... maintaining the integrity of the viral nucleic acids ... the recent Ebola epidemic in West ...
Breaking Biology Technology:ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 2Safe storage and transport of Ebola, Mers-CoV, and other viruses: Groundbreaking viral inactivation solution capable of preserving nucleic acids 3
... interpersonal skills, influence and collaboration, but when it comes right ... that runs right down the middle. As director of the ... Annie Stunden manages 500 staff. But because there ... in other departments on campus, a traditional chain of command ...
... looked at venture capital performance in the U.S. during 2004. , ... garnered its share of this investment as well as how the ... a more detailed look at how the life science industry in ... PricewaterhouseCoopers MoneyTree report. , ,Still, I was able to ferret ...
... the university's Center for Intelligent Maintenance Systems said ... in April. Professor Jay Lee told the Milwaukee Journal-Sentinel that ... not have good enough legal and other infrastructure to support ... said it would sell all the assets of its ...
Cached Biology Technology:Annie Stunden, CIO at the University of Wisconsin-Madison 2Annie Stunden, CIO at the University of Wisconsin-Madison 3Annie Stunden, CIO at the University of Wisconsin-Madison 4Midwest VC investment up in 2004, but number of deals down 2Midwest VC investment up in 2004, but number of deals down 3
(Date:9/16/2014)... GARDENS, Fla. , Sept. 16, 2014 /PRNewswire/ ... biometric identity management solutions, announced today the launch ... designed to authenticate the identity of an individual ... The Android-based Verifier Sentry rapidly reads credential documents ... holder,s ID by matching the biometric to a ...
(Date:9/16/2014)... foods, autumn harks a season of bounty. Fungi of ... collectors to woodlands in search of elusive but delectable ... allure of the treasure hunt, and their mysterious not-quite-meat, ... are the mushrooms which you are eating known to ... vastly underdocumented although some estimates range up to ...
(Date:9/15/2014)... so-called central dogma of molecular biologythat DNA makes ... explanation for how genetic information is deciphered and ... of course, the process is vastly more complicated ... ago by Nobel Laureate Francis Crick, co-discoverer of ... multiple types of RNA, three of whichmessenger RNA ...
Breaking Biology News(10 mins):Cross Match Launches New Identity Management Handheld Solution 2What's for dinner? Rapidly identifying undescribed species in a commercial fungi packet 2What's for dinner? Rapidly identifying undescribed species in a commercial fungi packet 3Scientists discover RNA modifications in some unexpected places 2
... MD, MPH, has been named the winner of the $100,000 ... 6,500 online votes from people across the globe determined the ... sequencing of newborns, emerged as the winner after six weeks ... for creating this competition and I am delighted to win. ...
... Columbia University Medical Center (CUMC) presented the 2012 ... Diane Mathis, PhD, both of Harvard Medical School, for ... underlying type 1 diabetes over the past three decades. ... Center, is Columbia,s top honor for excellence in diabetes ...
... has been 25 years since the identification of two proteins ... that revealed a group of related proteins. In recognition ... has published a series of articles that assess what we ... that research is headed. This superfamily was recognized in ...
Cached Biology News:Research gets real - Public votes determine winner of $100,000 research prize 2Columbia awards 2012 Naomi Berrie Award to Drs. Christophe Benoist & Diane Mathis 2Columbia awards 2012 Naomi Berrie Award to Drs. Christophe Benoist & Diane Mathis 3The Journal of Biological Chemistry commemorates an important 1987 discovery 2
... The ApopTag Fluorescein Direct ... detects apoptotic cells in situ ... The DNA fragments are tagged ... nucleotide. The kit provides fluorescence ...
... two color staining method for labeling DNA ... apoptotic cells by flow cytometry. The kit ... measuring apoptosis in cells including: positive and ... washing, reaction and rinsing buffers for processing ...
... and PowerPac 3000 system, 220-240 V, is used ... 50 cm vertical slab gel format. The system ... is capable of separating nucleic acids with single ... (IPC) assembly (IPC and bonded inner glass plate, ...
... agarose is used for second-dimension SDS-PAGE ... in place in PROTEAN Plus cells. ... to allow monitoring of electrophoresis runs. ... agarose in 1x Tris, glycine, SDS, ...
Biology Products: